Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 181 - 190 of 243
Alternative Name: Polidocanol Foam Permanent Contraception
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Fallopian Tube
Developer: Oregon Health & Science University
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HLL Lifecare Limited
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Vindico NanoBio Technology Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: Indian Council for Medical Research, Talwar Research Foundation
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: Progestin Vaginal Ring (PVR)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, Grunenthal
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: Mini-pill cream
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Viramal Limited
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: PGE2
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, Bayer HealthCare
Development Stage: Target Identification
Development Phase: Discovery and Early Development
Alternative Name: Quinacrine Sterilization (QS)
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: ISAF
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Other
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development

Pages

Displaying 51 - 60 of 70
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Innolytics LLC
Development Stage: Lead Optimization
PC6
Alternative Name: Proprotein convertase 6
Target
Hormonal: No
Developer: CONRAD, Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Alternative Name: Phosphodiesterase 3, 5, 9, PDE3A
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Vaginal Gel, Vaginal Ring
Developer: Ottawa Hospital Research Institute (OHRI)
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Vindico NanoBio Technology Inc.
Development Stage: Lead Optimization
Alternative Name: PGE2
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, Bayer HealthCare
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Other
Development Stage: Compound ID/Selection
Alternative Name: Retinoic acid receptor (RAR) antagonists
Target
User: Male
Hormonal: No
Duration Type: Short-acting
Developer: NICHD, Columbia University, University of Washington, University of Minnesota
Development Stage: Target Validation
Alternative Name: l-CDB-4022
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Development Stage: Lead Optimization
Alternative Name: Serum- and Glucocorticoid-Regulated Kinase
Target
User: Female
Hormonal: No
Developer: CONRAD, Imperial College, London
Development Stage: Target Identification

Pages

Displaying 91 - 100 of 121
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: HLL Lifecare Limited
Development Stage: Phase II
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: Indian Council for Medical Research, Talwar Research Foundation
Development Stage: Phase II
Alternative Name: Mini-pill cream
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Viramal Limited
Development Stage: Pre-clinical
Alternative Name: Quinacrine Sterilization (QS)
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: ISAF
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Tehran University
Development Stage: Pre-clinical
Alternative Name: Reversible inhibition of sperm under guidance (RISUG)
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Indian Council for Medical Research, Indian Institute of Technology, Kharagpur
Development Stage: Phase III
ROC
Alternative Name: Ulipristal acetate (UPA) Oral
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: HRA Pharma, NICHD
Development Stage: Phase II
Alternative Name: C31G Vaginal Gel
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: Adamis Pharmaceuticals
Development Stage: Phase III
Alternative Name: SCHIELD Biodegradable MPT Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: RTI International
Development Stage: Pre-clinical
Alternative Name: Shepard Medical Intra Vas Device (IVD)
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Shepherd Medical Company
Development Stage: Phase I

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV